Actively Recruiting
Study of Raludotatug Deruxtecan With or Without Bevacizumab Compared to Standard Platinum-Based Chemotherapy in Advanced High-Grade Ovarian, Peritoneal, or Fallopian Tube Cancer After PARP-Inhibitor Treatment
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-30
646
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating new treatments for advanced, high-grade ovarian cancer, including cancers that started in the ovaries, lining of the belly, or fallopian tubes. This trial focuses on participants whose cancer has spread and is difficult to remove surgically. The study compares a new medicine called raludotatug deruxtecan R-DXd, given with or without bevacizumab, to standard platinum-based chemotherapy with or without bevacizumab. The main goal is to see if R-DXd helps participants live longer and delay cancer growth compared to current treatments. Participants will be randomly assigned to receive either R-DXd intravenously with or without bevacizumab, or standard chemotherapy options including carboplatin, paclitaxel, gemcitabine, or pegylated liposomal doxorubicin, with or without bevacizumab. Treatments may continue for up to 2 years or until the cancer worsens or side effects prevent further treatment. Bevacizumab, if used, will be given every three weeks alongside the other therapies. During the trial, participants will have regular assessments to monitor cancer progression and overall survival for up to approximately 3 to 4 years. Researchers will track side effects, treatment responses, quality of life, and other health measures. Participants will undergo various evaluations including imaging, questionnaires, and lab tests to carefully observe their health and treatment effects throughout the study period.
CONDITIONS
Brief Title
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here